A carregar...
Assessment and optimization of respiratory syncytial virus prophylaxis in Connecticut, 1996–2013
Respiratory syncytial virus (RSV) causes seasonal respiratory infection, with hospitalization rates of up to 50% in high-risk infants. Palivizumab provides safe and effective, yet costly, immunoprophylaxis. The American Academy of Pediatrics (AAP) recommends palivizumab only for high-risk infants an...
Na minha lista:
| Publicado no: | Sci Rep |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Nature Publishing Group UK
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8139984/ https://ncbi.nlm.nih.gov/pubmed/34021214 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-021-90107-8 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|